Articles by Jennifer Chain

1. A Case For Paying Allogeneic Cell Therapy Product Donors 5/9/2025

   The debate over whether to pay donors for cell therapy starting materials comes down to four areas of disagreement: altruism, availability, ethics, and safety.

2. Hear Me Out — Cell Therapy GMP Starts With The Donor 1/9/2025

   Regulators also have indicated they expect allogeneic cell therapy donors to meet more rigid eligibility requirements and undergo screening.

3. Solving The Leukopak Supply Chain Issue With Cryopreservation 11/25/2024

   Allogeneic cell therapy developers report an alarming number of starting materials arrive at the wrong temperatures, late, or fail to arrive altogether.

4. What's In The Leukopak Matters For Cell Therapy Manufacturing 10/11/2024

   Advanced cell-based therapies are impossible without high-quality leukopaks from high-quality donors.